Sex-dependent Difference in the effect of metformin on colorectal cancer-specific mortality of Diabetic colorectal cancer patients

Jung Won Park, Jin Ha Lee, Ye Hyun Park, Soo Jung Park, Jae Hee Cheon, Won Ho Kim, Tae Il Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

AIM To assess factors associated with the higher effect of metformin on mortality in Diabetic colorectal cancer (CRC) patients, since the factors related to the effectiveness of metformin have not been identified yet. METHODS Between January 2000 and December 2010, 413 patients Diagnosed with both stage 3/4 CRC and Diabetes mellitus were identified. Patients' demographics and clinical characteristics were analyzed. The effect of metformin on CRC-specific mortality and the interactions between metformin and each adjusted factor were evaluated. RESULTS Total follow-up duration was meDian 50 mo (range: 1-218 mo). There were 85 deaths (45.9%) and 72 CRC-specific deaths (38.9%) among 185 patients who used metformin, compared to 130 total deaths (57.0%) and 107 CRC-specific deaths (46.9%) among 228 patients who Did not use metformin. In multivariate analysis, survival benefit associated with metformin administration was identified (HR = 0.985, 95%CI: 0.974-0.997, p = 0.012). Interaction test between metformin and sex after adjustment for relevant factors revealed that female CRC patients taking metformin exhibited a significantly lower CRC-specific mortality rate than male CRC patients taking metformin (HR = 0.369, 95%CI: 0.155-0.881, p = 0.025). Furthermore, subgroup analysis revealed significant Differences in CRC-specific mortality between the metformin and non-metformin groups in female patients (HR = 0.501, 95%CI: 0.286-0.879, p = 0.013) but not male patients (HR = 0.848, 95%CI: 0.594-1.211, p = 0.365). There were no significant interactions between metformin and other adjusted factors on CRC-specific mortality. CONCLUSION We showed a strong sex-dependent Difference in the effect of metformin on CRC-specific mortality in advanced stage CRC patients with Diabetes.

Original languageEnglish
Pages (from-to)5196-5205
Number of pages10
JournalWorld Journal of Gastroenterology
Volume23
Issue number28
DOIs
Publication statusPublished - 2017 Jul 28

Fingerprint

Metformin
Sex Characteristics
Colorectal Neoplasms
Mortality
Diabetes Mellitus
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

@article{57564009d47a4034956ff30257d0f4e4,
title = "Sex-dependent Difference in the effect of metformin on colorectal cancer-specific mortality of Diabetic colorectal cancer patients",
abstract = "AIM To assess factors associated with the higher effect of metformin on mortality in Diabetic colorectal cancer (CRC) patients, since the factors related to the effectiveness of metformin have not been identified yet. METHODS Between January 2000 and December 2010, 413 patients Diagnosed with both stage 3/4 CRC and Diabetes mellitus were identified. Patients' demographics and clinical characteristics were analyzed. The effect of metformin on CRC-specific mortality and the interactions between metformin and each adjusted factor were evaluated. RESULTS Total follow-up duration was meDian 50 mo (range: 1-218 mo). There were 85 deaths (45.9{\%}) and 72 CRC-specific deaths (38.9{\%}) among 185 patients who used metformin, compared to 130 total deaths (57.0{\%}) and 107 CRC-specific deaths (46.9{\%}) among 228 patients who Did not use metformin. In multivariate analysis, survival benefit associated with metformin administration was identified (HR = 0.985, 95{\%}CI: 0.974-0.997, p = 0.012). Interaction test between metformin and sex after adjustment for relevant factors revealed that female CRC patients taking metformin exhibited a significantly lower CRC-specific mortality rate than male CRC patients taking metformin (HR = 0.369, 95{\%}CI: 0.155-0.881, p = 0.025). Furthermore, subgroup analysis revealed significant Differences in CRC-specific mortality between the metformin and non-metformin groups in female patients (HR = 0.501, 95{\%}CI: 0.286-0.879, p = 0.013) but not male patients (HR = 0.848, 95{\%}CI: 0.594-1.211, p = 0.365). There were no significant interactions between metformin and other adjusted factors on CRC-specific mortality. CONCLUSION We showed a strong sex-dependent Difference in the effect of metformin on CRC-specific mortality in advanced stage CRC patients with Diabetes.",
author = "Park, {Jung Won} and Lee, {Jin Ha} and Park, {Ye Hyun} and Park, {Soo Jung} and Cheon, {Jae Hee} and Kim, {Won Ho} and Kim, {Tae Il}",
year = "2017",
month = "7",
day = "28",
doi = "10.3748/wjg.v23.i28.5196",
language = "English",
volume = "23",
pages = "5196--5205",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "28",

}

Sex-dependent Difference in the effect of metformin on colorectal cancer-specific mortality of Diabetic colorectal cancer patients. / Park, Jung Won; Lee, Jin Ha; Park, Ye Hyun; Park, Soo Jung; Cheon, Jae Hee; Kim, Won Ho; Kim, Tae Il.

In: World Journal of Gastroenterology, Vol. 23, No. 28, 28.07.2017, p. 5196-5205.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sex-dependent Difference in the effect of metformin on colorectal cancer-specific mortality of Diabetic colorectal cancer patients

AU - Park, Jung Won

AU - Lee, Jin Ha

AU - Park, Ye Hyun

AU - Park, Soo Jung

AU - Cheon, Jae Hee

AU - Kim, Won Ho

AU - Kim, Tae Il

PY - 2017/7/28

Y1 - 2017/7/28

N2 - AIM To assess factors associated with the higher effect of metformin on mortality in Diabetic colorectal cancer (CRC) patients, since the factors related to the effectiveness of metformin have not been identified yet. METHODS Between January 2000 and December 2010, 413 patients Diagnosed with both stage 3/4 CRC and Diabetes mellitus were identified. Patients' demographics and clinical characteristics were analyzed. The effect of metformin on CRC-specific mortality and the interactions between metformin and each adjusted factor were evaluated. RESULTS Total follow-up duration was meDian 50 mo (range: 1-218 mo). There were 85 deaths (45.9%) and 72 CRC-specific deaths (38.9%) among 185 patients who used metformin, compared to 130 total deaths (57.0%) and 107 CRC-specific deaths (46.9%) among 228 patients who Did not use metformin. In multivariate analysis, survival benefit associated with metformin administration was identified (HR = 0.985, 95%CI: 0.974-0.997, p = 0.012). Interaction test between metformin and sex after adjustment for relevant factors revealed that female CRC patients taking metformin exhibited a significantly lower CRC-specific mortality rate than male CRC patients taking metformin (HR = 0.369, 95%CI: 0.155-0.881, p = 0.025). Furthermore, subgroup analysis revealed significant Differences in CRC-specific mortality between the metformin and non-metformin groups in female patients (HR = 0.501, 95%CI: 0.286-0.879, p = 0.013) but not male patients (HR = 0.848, 95%CI: 0.594-1.211, p = 0.365). There were no significant interactions between metformin and other adjusted factors on CRC-specific mortality. CONCLUSION We showed a strong sex-dependent Difference in the effect of metformin on CRC-specific mortality in advanced stage CRC patients with Diabetes.

AB - AIM To assess factors associated with the higher effect of metformin on mortality in Diabetic colorectal cancer (CRC) patients, since the factors related to the effectiveness of metformin have not been identified yet. METHODS Between January 2000 and December 2010, 413 patients Diagnosed with both stage 3/4 CRC and Diabetes mellitus were identified. Patients' demographics and clinical characteristics were analyzed. The effect of metformin on CRC-specific mortality and the interactions between metformin and each adjusted factor were evaluated. RESULTS Total follow-up duration was meDian 50 mo (range: 1-218 mo). There were 85 deaths (45.9%) and 72 CRC-specific deaths (38.9%) among 185 patients who used metformin, compared to 130 total deaths (57.0%) and 107 CRC-specific deaths (46.9%) among 228 patients who Did not use metformin. In multivariate analysis, survival benefit associated with metformin administration was identified (HR = 0.985, 95%CI: 0.974-0.997, p = 0.012). Interaction test between metformin and sex after adjustment for relevant factors revealed that female CRC patients taking metformin exhibited a significantly lower CRC-specific mortality rate than male CRC patients taking metformin (HR = 0.369, 95%CI: 0.155-0.881, p = 0.025). Furthermore, subgroup analysis revealed significant Differences in CRC-specific mortality between the metformin and non-metformin groups in female patients (HR = 0.501, 95%CI: 0.286-0.879, p = 0.013) but not male patients (HR = 0.848, 95%CI: 0.594-1.211, p = 0.365). There were no significant interactions between metformin and other adjusted factors on CRC-specific mortality. CONCLUSION We showed a strong sex-dependent Difference in the effect of metformin on CRC-specific mortality in advanced stage CRC patients with Diabetes.

UR - http://www.scopus.com/inward/record.url?scp=85026519024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026519024&partnerID=8YFLogxK

U2 - 10.3748/wjg.v23.i28.5196

DO - 10.3748/wjg.v23.i28.5196

M3 - Article

C2 - 28811714

AN - SCOPUS:85026519024

VL - 23

SP - 5196

EP - 5205

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 28

ER -